JP2024514935A5 - - Google Patents

Info

Publication number
JP2024514935A5
JP2024514935A5 JP2023564409A JP2023564409A JP2024514935A5 JP 2024514935 A5 JP2024514935 A5 JP 2024514935A5 JP 2023564409 A JP2023564409 A JP 2023564409A JP 2023564409 A JP2023564409 A JP 2023564409A JP 2024514935 A5 JP2024514935 A5 JP 2024514935A5
Authority
JP
Japan
Prior art keywords
frα
composition according
subject
less
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514935A (ja
Filing date
Publication date
Priority claimed from PCT/EP2021/060749 external-priority patent/WO2021214329A1/en
Priority claimed from GBGB2109550.0A external-priority patent/GB202109550D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/060693 external-priority patent/WO2022223784A1/en
Publication of JP2024514935A publication Critical patent/JP2024514935A/ja
Publication of JP2024514935A5 publication Critical patent/JP2024514935A5/ja
Pending legal-status Critical Current

Links

JP2023564409A 2021-04-23 2022-04-22 IgE抗体を含む組成物 Pending JP2024514935A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
EPPCT/EP2021/060749 2021-04-23
GBGB2109550.0A GB202109550D0 (en) 2021-07-01 2021-07-01 Composition
GB2109550.0 2021-07-01
PCT/EP2022/060693 WO2022223784A1 (en) 2021-04-23 2022-04-22 Composition comprising an ige antibody

Publications (2)

Publication Number Publication Date
JP2024514935A JP2024514935A (ja) 2024-04-03
JP2024514935A5 true JP2024514935A5 (cg-RX-API-DMAC7.html) 2025-04-18

Family

ID=81750377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564409A Pending JP2024514935A (ja) 2021-04-23 2022-04-22 IgE抗体を含む組成物

Country Status (10)

Country Link
US (1) US20240190955A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326770A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514935A (cg-RX-API-DMAC7.html)
KR (1) KR20240001136A (cg-RX-API-DMAC7.html)
AU (1) AU2022263376A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021873A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215850A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012557A (cg-RX-API-DMAC7.html)
WO (1) WO2022223784A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309456B (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
BR112019023909A8 (pt) 2017-05-16 2023-04-11 Immunogen Inc Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
GB202006093D0 (en) * 2020-04-24 2020-06-10 King S College London Composition

Similar Documents

Publication Publication Date Title
US20180161293A1 (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
JP2007515469A5 (cg-RX-API-DMAC7.html)
JPH03188021A (ja) レトロウイルスを撲滅するための医薬品およびその製造法
WO2015090162A1 (zh) 一种含有阿达木单抗的药物组合物
WO2022052874A1 (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
JP2017533274A (ja) メトトレキサート製剤
CN103877101A (zh) 葫芦素在制备抗肿瘤药物中的应用
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
US11974993B2 (en) Solution formulations of CX-011
SK129999A3 (en) Pharmaceutical composition, preparation process and use thereof
US9919053B2 (en) Cabazitaxel composition
US12533373B2 (en) β-glucan composition and use therefor
US20250049869A1 (en) Use of auricularia auricula total polysaccharide or monomeric polysaccharide in preparation of pd-l1 inhibitor
CN120390655A (zh) 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途
CN111393278B (zh) 一种长松萝衍生物及其在制备治疗胆囊癌药物中的用途
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
JPS6310685B2 (cg-RX-API-DMAC7.html)
CN113082203B (zh) 一种免疫抑制剂单克隆抗体的液体制剂
WO2019114125A1 (en) A novel quinochalcone compound and uses thereof for treating cancer or inflammation
CN119700764B (zh) 恩波吡维铵在制备抗基孔肯亚病毒感染药物中的应用
CN104000835A (zh) P糖蛋白抑制剂
CN117442590A (zh) 包含紫檀芪的药物组合物及其制备方法与制药用途
CN111728960B (zh) 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用
JPS6213922B2 (cg-RX-API-DMAC7.html)
CN111065405A (zh) 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法